Accessibility & Convenience,
In Support of
Individual Goals

Program Highlights

Terrestrial Bio’s lead program is focused on GLP-1s, a class of medicines used to treat obesity and metabolic disease. Research demonstrates that the Terrestrial’s microarray patch (MAP) is capable of delivering semaglutide, a GLP-1 receptor agonist, with bioavailability comparable to subcutaneous injection. Additionally, according to the company’s recent GLP-1 human factors study, nearly all participants expressed a preference for the patch applicator over traditional injection devices.